[Summary] Gene therapy developer
Kanglin Biotechnology (Hangzhou) Co., Ltd. was founded in August 2015 with a registered capital of RMB 50 million, initially located in the High-tech Incubator of Hangzhou Economic and Technological Development Zone. To accelerate its growth, the company relocated to Hangzhou Eastern Medical Port Town in October 2017. Its R&D center now covers more than 1,700 square meters, including a GMP workshop of over 400 square meters built to CFDA standards.
Kanglin Biotechnology has assembled an outstanding R&D and management team. The expert team is composed of professors from renowned American research institutions and senior corporate executives, all of whom have led multiple large-scale research projects of the U.S. National Institutes of Health (NIH) and possess extensive R&D and management experience, providing strong support for the company's technology development and product upgrading. Two senior executives of the company were respectively selected for the 2017 Hangzhou "115" Plan for Introducing Overseas (Foreign) Expertise and the second batch of Hangzhou's "521" Global Talent Recruitment Plan. Among the team, 19% hold doctoral degrees, 50% hold master's degrees, and 31% hold bachelor's degrees, with a well-established research, quality inspection, and administrative workforce.
Kanglin Biotechnology focuses on the R&D of gene therapy and cell therapy technologies. Its current project, "Functional Cure of AIDS," has received support from the National 13th Five-Year Plan Major Science and Technology Project "Prevention and Treatment of Major Infectious Diseases such as AIDS and Viral Hepatitis." Meanwhile, the company has leading technologies in lentiviral vector preparation, T-cell transduction, and T-cell gene editing, and is particularly skilled in large-scale clinical-grade lentiviral vector preparation. Kanglin Biotechnology's lentivirus production platform is the cornerstone of its development; the company has invested substantial manpower and resources to develop a clinical-grade, high-purity lentivirus production process, with technology reaching a leading level. Adhering to a strategy of parallel development of new drug R&D and CRO, the company both independently develops gene therapy technologies for the functional cure of AIDS and provides clinical-grade lentivirus packaging services to peers engaged in gene therapy and cell therapy.
Guided by the vision of "Conquering Intractable Diseases, Saving Lives," Kanglin Biotechnology will continue to forge ahead on the path of gene therapy and pursue excellence!
What does Kanglin Biotechnology (Hangzhou) Co., Ltd. require? Who is Kanglin Biotechnology hiring? Kanglin Biotechnology recruitment: Factory Production占比最多占42.4%,其次是Biology/Pharmaceutical/Chemical/Environmental Protection占33.3%. What education can get in at Kanglin Biotechnology? 本科占比最多占75.8%,其次是大专占15.2%. High education required at Kanglin Biotechnology? 硕士占6.1%,博士占3%. Work experience required at Kanglin Biotechnology? 1-3年占比最多占57.6%,其次是3-5年占30.3%. Where are the job locations at Kanglin Biotechnology? 杭州占比最多占75.8%,其次是广州占24.2%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows